A Phase IV, Multicentre, Open-label, Single-arm Study to Investigate the Efficacy, Safety and Durability of Faricimab (RO6867461) in Caucasian Patients With Polypoidal Choroidal Vasculopathy
Latest Information Update: 02 Dec 2024
Price :
$35 *
At a glance
- Drugs Faricimab (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Registrational; Therapeutic Use
- Acronyms MONDEGO
- 02 Dec 2024 New trial record